Nebenwirkungen · Nucala
Nucala 100 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 40
HOS-132625 · Präparat HOS-097252
In placebo-controlled studies the incidence of local injection site reactions with mepolizumab 100 mg subcutaneous and placebo was 8% and 3%, respectively. These events were all non-serious, mild to moderate in intensity and the majority resolved within a few days. Local injection site reactions occurred mainly at the start of treatment and within the first 3 injections with fewer reports on subsequent injections. The most common manifestations reported with these events included pain, erythema, swelling, itching, and burning sensation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T16:02:00Z · SHA-256 297766dd530d777167969a87af3c0ff120dce3cd78dcb8c4ddbec012a3bcb033 · Passage 41120a37d45d212938c75cac0ca09d60c97c16db478bbfdb89360e873a2103d3 · Zeichen 7171–7713 im Abschnitt